Dianthus Therapeutics, Inc. DNTH
Set alert
82.16 USD -0.22 -0.27%
As of Nov 2, 10:48 AM ET
81.79 Day range 84.56
32.28 52-week range 117.88
- YTD
- +99.37%
- 1 year
- +134.88%
- Open
- 83.66
- Prev close
- 82.38
- Mkt cap
- 4.51B
- Vol
- 110.82K
- Avg vol
- 813.33K
- EPS
- -4.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 81.79
- High
- 84.56
- Forward P/E
- -17.87
- Beta
- 0.18
- Short ratio
- 9.16
- Inst. own
- 128.66%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 93.30
- 200-d avg
- 84.85
- 1y target
- 139.06
3M chart
Events in this range
- Aug 4, 2026Earnings: -0.9; estimate -0.84628; surprise -6.35%
- Aug 6, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 6, 2026Rating: Truist Securities · Buy → Buy
- Sep 4, 2026Rating: Citigroup · — → Buy
- Sep 11, 2026Rating: JP Morgan · — → Overweight
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 27, 2026Rating: Roth Capital · — → Buy
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 11, 2026 | 2 months ago |
Financial health
Altman Z-Score
67.31 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -9.8×
FY 2016 5y median -8.5× FY 2025
P/S 765×
FY 2016 5y median 116× FY 2025
P/B 3.2×
FY 2016 5y median 1.4× FY 2025
P/FCF -12.0×
FY 2016 5y median -4.0× FY 2025
EV/EBITDA -9.3×
FY 2016 5y median -8.3× FY 2025
EV/Sales 741×
FY 2016 5y median 75.7× FY 2025
FCF Yield -8.3%
FY 2016 5y median -25.0% FY 2025
Profitability
Gross Margin 100.0%
FY 2016 5y median 100.0% FY 2025
Operating Margin -8739.3%
FY 2016 5y median -1633.7% FY 2025
Net Margin -7973.3%
FY 2016 5y median -1362.8% FY 2025
ROE -32.9%
FY 2016 5y median -25.8% FY 2025
ROIC -35.5%
FY 2016 5y median -28.6% FY 2025
ROA -30.6%
FY 2016 5y median -24.3% FY 2025
Growth (YoY)
Revenue -67.3%
FY 2016 FY 2025
Operating Income -74.7%
FY 2016 FY 2025
EPS (diluted) -64.7%
FY 2016 FY 2025
Free Cash Flow -65.1%
FY 2016 FY 2025
Financial Health
Current Ratio 13.3×
FY 2016 5y median 15.2× FY 2025
Quick Ratio 13.3×
FY 2016 5y median 15.2× FY 2025
Debt / Equity 0.0×
FY 2016 5y median 0.0× FY 2025
Net Debt / EBITDA 0.3×
FY 2016 5y median 0.5× FY 2025
Interest Coverage 0.0×
FY 2016 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31